fda glp-1 warning letters november 2025 Trends In FY FDA Issues Warning Letters to

Extended-release and combination therapies are being developed to provide sustained glucose control and weight management

Hair loss is a common concern on GLP-1 medications

Holman RR, Bethel MA, Mentz RJ, EXSCEL Study Group, et al

Liraglutide attenuates obese-associated breast cancer cell proliferation via inhibiting PI3K/Akt/mTOR signaling pathway

In summary, the quest for a monthly GLP-1 injection faces a balancing act: delivering a large dose steadily and safely, avoiding local and systemic side effects, preserving drug stability, and doing it all in a manufacturable, patient-friendly format

When travelling eastward (e.g., UK to Asia), your day becomes shorter, potentially requiring a dose sooner than 24 hours after your previous injection